SapVax will develop a suite of first-in-class cancer vaccines based on a novel peptide platform technology. It has a pipeline of similar vaccines in development with lead vaccines targeting a key antigen expressed in a broad range of cancers and Epstein-Barr virus proteins strongly associated with certain cancers, including nasopharyngeal cancer, lymphoma, and gastric cancer.
The research was funded by the Maurice Wilkins Centre for Molecular Biodiscovery at the University of Auckland.
“The Auckland team’s discoveries present a novel platform for overcoming traditional barriers to developing cancer vaccines,” says Baiju R Shah, Chief Executive Officer of BioMotiv” We look forward to accelerating their work into breakthrough therapies through SAPVax.”
“We are delighted to be partnering with BioMotiv to launch SapVax and develop this exciting new platform into clinical candidates, to further the exciting promise of cancer immunotherapy”, says Will Charles, the General Manager of Technology Development at Uniservices.
Co-founded by Margaret Brimble, Neuren currently has a candidate, trofinetide in phase-2 clinical trials for Rett syndrome, fragile X syndrome, traumatic brain injury and concussion.